D. Boral Capital Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They currently have a $30.00 target price on the stock.

IBRX has been the topic of a number of other research reports. BTIG Research assumed coverage on shares of ImmunityBio in a report on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd.

ImmunityBio Trading Up 9.0 %

Shares of IBRX opened at $3.62 on Friday. The business’s 50-day moving average price is $3.00 and its 200 day moving average price is $3.82. The stock has a market capitalization of $2.52 billion, a P/E ratio of -3.93 and a beta of 0.94. ImmunityBio has a 1-year low of $2.28 and a 1-year high of $10.53.

Institutional Trading of ImmunityBio

A number of hedge funds have recently made changes to their positions in the stock. Stephens Inc. AR acquired a new position in ImmunityBio in the 4th quarter valued at approximately $26,000. Cibc World Markets Corp purchased a new position in shares of ImmunityBio during the 4th quarter valued at $35,000. Maia Wealth LLC acquired a new position in shares of ImmunityBio in the fourth quarter worth $37,000. Schechter Investment Advisors LLC purchased a new stake in shares of ImmunityBio during the fourth quarter worth $38,000. Finally, Captrust Financial Advisors acquired a new stake in ImmunityBio during the third quarter valued at $41,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.